H Program
  Operations Staff 301-594-1190) of the SR determination; <br>
  Study may not begin until FDA approves IDE and IRB approves the study.<br>
    Sponsor and investigator(s) must comply with IDE regulations [21 CFR part 
    812], as well as informed consent and IRB regulations [21 CFR parts 50 and 
    56].</p>
</blockquote>

<p><b>If the IRB decides the study is Nonsignificant Risk:</b></p>

<p>1. IRB proceeds to review study applying requisite criteria [21 CFR 56.111] </p>

<p>2. If t